RA
Rafarma Pharmaceuticals, Inc.
RAFA · OTC
$0.02 -7.69% (-$0.00)
1M +26.25%
Market Cap $2.28M
P/E Ratio 6.54x
Div. Yield -
ROE 3.34%
Bulios Fair Price
$0.04
66.7% upside
Current Price
$0.024
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RAFA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
100 /100
Cheap P/B 0.22x
P/S 0.25x
P/E 6.54x
Growth
0 /100
Declining Rev. growth 47.74%
Book val. growth 48.73%
EPS growth 58.63%
Profitability
14 /100
Weak FCF margin 0.17%
Op. margin 5.33%
Gross margin 8.29%
Quality
25 /100
Poor Asset turnover 0.77x
ROA 2.91%
ROIC 3.80%
Debt
90 /100
Low Current ratio 1.13x
Net debt/EBITDA -0.07x
Debt/Equity 0.00x
Stability
45 /100
Moderate Profitable years 6
EPS volatility 65.85%
Beta 0.70x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RAFA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sergey Brusnitsin
Employees
700
Headquarters
Sandy